Sign in
Active, not recruitingNo phase

Biomarkers of Cancer-Associated Myositis

Key facts

Who runs it
Azienda USL Reggio Emilia - IRCCS
Where
Italy2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
50 people enrolled
Started
13 Jun 2019
Expected to end
31 Dec 2026
Type of study
Observational, 3 groups
Record updated
5 May 2026

Who can take part

Age
40 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Age > 40 years
  • Diagnosis of DM
  • Informed Consent

Who cannot take part

  • Chemotherapy at the time of the peripheral venous blood draw
  • Therapy with biologic drugs at the time of the peripheral venous blood draw
  • Necrotizing autoimmune myopathy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The project is about dermatomyositis (DM), an autoimmune disease characterized by inflammation in the skeletal muscles and skin. Patients with DM have an increased risk of cancer, with a cancer incidence between 5.5% and 42%. Cancers in these patients are one of the leading causes of death. Some myositis-specific autoantibodies have been discovered and some of them are associated with cancer development. However, DM patients negative for all the known autoantibodies can also develop cancer. The Investigator hypothesized that antibodies against plasma membrane antigens and soluble immune checkpoints can be responsible for the association between cancers and autoimmunity. Therefore, the present study aimed to identify novel antigens and immunological pathways in patients with DM with cancer versus patients with DM without cancer, to identify those patients who need cancer screening. The Investigators focus on soluble immune checkpoint molecules and autoantibodies directed against plasma membrane antigens.

The 3 groups in the trial

  • DM without cancer

    Patients with DM who do not have cancer at diagnosis and in the 3-year follow-up period

  • DM with cancer

    Patients with DM who have cancer at diagnosis or in the 3-years before or after DM diagnosis

  • Healthy controls

    Subjects without known cancer, autoimmune diseases and infections

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Plasma Membrane Antigens as Trigger in Cancer-associated Myositis
Record updated
5 May 2026